Dr. Ruan Discusses Biomarkers in MCL

Jia Ruan, MD, PhD
Published: Monday, Mar 19, 2018



Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma (MCL).

One of the challenges that persists in the treatment of patients with MCL is selection for therapies. Ruan says biomarkers need to be identified to predict risk or responsiveness to agents or combinations of agents. This would require an additional and concerted effort, Ruan says, and would be best investigated in a prospective clinical trial.

Ruan suggests that collecting clinical, pathological, and biomarker data in a prospective clinical trial could subsequently lead to more specific treatment regimens for patients with MCL.
 
SELECTED
LANGUAGE


Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma (MCL).

One of the challenges that persists in the treatment of patients with MCL is selection for therapies. Ruan says biomarkers need to be identified to predict risk or responsiveness to agents or combinations of agents. This would require an additional and concerted effort, Ruan says, and would be best investigated in a prospective clinical trial.

Ruan suggests that collecting clinical, pathological, and biomarker data in a prospective clinical trial could subsequently lead to more specific treatment regimens for patients with MCL.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x